Expression of PD-L1 and PD-L2 in tumors and clinical significance
| Cancer | No. of samples | PD-L1 (%) | PD-L2 (%) | Clinical association | Reference |
|---|---|---|---|---|---|
| Renal cell carcinoma | 196 | 66 | 3-fold increased mortality | (78) | |
| Tumor-infiltrating lymphocytes | 59 | 3.6-fold increased mortality | |||
| Non–small cell lung cancer | 52 | 100 | 100 | None | (79) |
| Breast cancer | 44 | 50 | Associated with grade III, and estrogen/progesterone receptors | (80) | |
| Tumor infiltrating lymphocytes | 34 | Associated with tumor size, grade III, Her2/neu positive status | |||
| Gastric carcinoma | 102 | 42.2 | Associated with tumor size, invasion, metastasis, and survival | (82) | |
| Bladder urothelial carcinoma | 65 | 100 | Associated with high recurrence and poor survival | (84) | |
| Bladder urothelial carcinoma | 280 | 36.1 | Associated with high-grade tumor infiltrating mononuclear cells | (83) | |
| Ovarian cancer | 70 | 68.6 | Poor prognostic factor for survival | (81) | |
| Inversely associated with intraepithelial CD8 cells | |||||
| 37.1 | None | ||||
| Pancreatic cancer | 51 | 38.2 | Associated with poor survival | (85) | |
| Inversely associated with tumor-infiltrating CD8 cells | |||||
| 27.5 | None |